Yiling Pharmaceutical Co., Ltd. Donated Lianhua Qingwen Capsules Worth RMB 2.96 Million Yuan to the SCO to Support its Prevention and Control of the Epidemic.
Mr. Vladimir Norov, Secretary-General of the Shanghai Cooperation Organization (SCO) (right) presents a letter of thanks to Zhang Yunling, Executive Deputy General Manager of Yiling Pharmaceutical Co., Ltd. on August 5, in recognition of the outstanding contribution to the prevention and control of COVID-19 in the SCO member countries.
The SCO Secretariat held a commendation meeting for the SCO Public Welfare Long March in Beijing on August 5. Vladimir Norov, Secretary-General of the SCO, presented Outstanding Contribution Award to Yiling Pharmaceutical Co., Ltd. (Yiling Pharmaceutical) in recognition of its outstanding contribution to the prevention and control of the epidemic in the SCO members.
Yiling Pharmaceutical donated Lianhua Qingwen Capsules worth RMB 2.96 million Yuan (USD 423,000 Dollars) to the SCO Secretariat to support the prevention and control of COVID-19 in the SCO members. A total of 200,000 boxes of Lianhua Qingwen Capsules were distributed to these countries.
Mr. Norov praised highly of China's friendly assistance to the SCO member countries and other countries at the donation ceremony. He thanked Yiling Pharmaceutical for its important contribution to the SCO Secretariat and members. China's successful experience in the fight against COVID-19 has provided a good reference for the SCO countries. During the prevention and control of COVID-19 in China, traditional Chinese medicine has demonstrated its unique advantages and made important contributions, of which Lianhua Qingwen is one of the representatives. It is believed that the 200,000 boxes of Lianhua Qingwen Capsules donated by Yiling Pharmaceutical will play an important role in the epidemic prevention and control in all the countries.
Mr. Norov mentioned that he learned that Yiling Pharmaceutical, as the representative for the internationalization of traditional Chinese medicine enterprises, had not only actively participated in China's domestic epidemic prevention and control, but also been committed to making contributions to the international fight against the epidemic, by donating epidemic prevention materials worth of more than RMB 20 million Yuan to support the epidemic prevention and control at home and abroad, so as to bear the social responsibility of Chinese enterprises.
It is learned that since the outbreak of COVID-19, Lianhua Qingwen Capsule (Granule), patented traditional Chinese medicine produced by Yiling Pharmaceutical has been recommended by the national authority and more than 20 provinces and cities for the diagnosis and treatment of COVID-19, and widely used in Huoshen Mountain Hospital, Leishen Mountain Hospital, compartment hospitals and other medical institutions. Internationally, Lianhua Qingwen has been approved for launch in more than 10 countries and regions such as Canada, Indonesia, Brazil, and Romania and also its registration work started in more than 40 countries around the world.
Previously, the study result of Prospective, Multicenter, Randomized, Controlled Clinical Study on the Treatment of Novel Coronavirus Pneumonia with Traditional Chinese Medicine Lianhua Qingwen conducted by Academicians Zhong Nanshan, Li Lanjuan, and Zhang Boli jointly with 23 hospitals to participate in the diagnosis and treatment of COVID-19, including the People's Hospital of Wuhan University, Wuhan Jinyintan Hospital, and First Affiliated Hospital of Guangzhou Medical University was published in the Plant Medicine, one of European authority magazines. The related research results show that Lianhua Qingwen can significantly improve the elimination rates of fever, fatigue, cough and other clinical symptoms of COVID-19, significantly reduce the pulmonary lesions, shorten the duration of the symptoms, and improve the clinical cure rate of COVID-19.